Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

230 targets multiple subtypes of the receptor for somatostatin (sst), a hormone that controls the pituitary gland. Its highest affinity is to sst5, a receptor subtype frequently expressed by the pituitary tumors associated with Cushing's disease. Currently approved somatostatin analogs preferentially bind to sst2 and are not effective in Cushing's disease(6).

SOM230 is currently being studied as a twice-daily sc injection, as well as a long-acting release (LAR) once-monthly intramuscular injection for the treatment of multiple disease types, including Cushing's disease, carcinoid syndrome and acromegaly(10).

Because it is an investigational compound, the safety and efficacy profile of SOM230 has not yet been established. Access to this investigational compound is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. There is no guarantee that SOM230 will become commercially available(6).

Information about Novartis clinical trials for SOM230 can be obtained by healthcare professionals at www.pasporttrials.com.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "will," "planned," "potential," or similar expressions, or by express or implied discussions regarding regulatory submissions or approvals for SOM230, or the timing of such submissions or approvals, or regarding potential future revenues from SOM230. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with SOM230 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guar
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Nov. 22, 2014  Sprout Pharmaceuticals today announced positive preliminary ... women treated with flibanserin up to 200 mg at bedtime ... presented at the 20 th Annual Fall Scientific Meeting ... in Miami . ... the Complete Response Letter and the Formal Dispute Resolution that ...
(Date:11/22/2014)... -- New data demonstrates that flibanserin, a novel, non-hormonal medicine ... sexual dysfunction, Hypoactive Sexual Desire Disorder (HSDD), does not ... women when taken at bedtime. The data was presented ... America,s (SMSNA) 20th Annual Fall Scientific Meeting ... SMSNA accepted this study as a late breaking abstract ...
(Date:11/22/2014)... MONMOUTH JUNCTION, N.J. , Nov. 21, 2014 ... immunotherapy company commercializing its European Union approved CytoSorb® ... countries worldwide, was awarded the Beacon of Light ... Annual Awards Celebration.  Dr. ... stated, "It is an honor to be recognized ...
Breaking Medicine Technology:Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... Inc. is pleased,to announce the dosing of the first ... study of AEG35156, a second generation antisense,therapeutic targeting XIAP, ... The study, made possible, in part, by funding ... 1-2, Multicenter, Open-Label Study,of the X- Linked Inhibitor of ...
... July 30 Anpath Group, Inc.,(OTC Bulletin Board: ... Inc. (ESI) announced that its EnviroTru(R),disinfectant has been ... Services (DMS) in the State of Florida. The ... LLC(TM) ( http://www.aworldofgreen.com ),worked with the ...
Cached Medicine Technology:Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156 2Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156 3Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 3
(Date:11/22/2014)... November 23, 2014 A classic black prom ... the most famous dress suppliers, has unveiled its new items ... dresses are now offered at a big discount, up to ... offer. , The new black prom dresses, made with ... to meet the needs of all customers, the company provides ...
(Date:11/22/2014)... Recently, Locks-Magnetic.com , one of ... promotion of mag locks for glass doors online. In ... on these fresh products. Customers can get more information ... doors are in excellent performance. Customers who want to ... soon as possible. They also can enjoy the ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 BambooFlooringChina.com ... the company has proudly released its new collection of ... discounted rates, up to 29% off. , According ... and sturdy tree-like grass, making it a highly renewable resource. ... products have a mixing color which comes from natural bamboo ...
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand ... wedding dresses; the business offers a wide range of ... ladies worldwide, allowing them to create multiple looks easily. ... this new collection of chic wedding dresses has been ... offered at discounted rates now. Dylan Queen can always ...
(Date:11/22/2014)... 22, 2014 Setria® Glutathione is ... approved it for use “as a therapeutically active ... within the Therapeutic Goods (Listing) Notice 2014 (No. ... Hakko’s Setria® Glutathione will be exclusivity distributed in ... sources and imports fine chemicals to Australian manufacturers. ...
Breaking Medicine News(10 mins):Health News:New Black Prom Dresses from BellasDress.com 2Health News:Discounted Mag Locks for Glass Doors Revealed by Locks-Magnetic.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... to consider risks of hormone treatment, inform patients ... used class of prostate cancer drugs called gonadotropin-releasing hormone ... stroke and sudden death in men, a U.S. Food ... initial findings from a preliminary and ongoing analysis of ...
... 3 May 2010 [Vienna, Austria] Organizers of the XVIII ... Clinton, founder of the William J. Clinton Foundation and 42nd ... Aaron Motsoaledi will be among 19 high-level speakers who will ... AIDS 2010 will take place from 18 to 23 July ...
... will save lives this summer, if everything goes as planned ... been turned, so to speak, into a rudimentary centrifuge that ... without electricity. Rice sophomore Lila Kerr and freshman ... two months this summer as part of Beyond Traditional Borders ...
... Knowing your children,s friends and good communication are key, ... Parents can play an important role in preventing their ... and getting to know their friends, a new study ... with their children could have a substantial impact on ...
... cancers are four times more likely to develop Post-Traumatic ... Childhood Cancer Survivors Study has found. The study ... were diagnosed with cancer between 1970 and 1986 and ... study found that 589 survivors, or 9 percent, reported ...
... An in vivo study shows for the first time ... that mirrors the signaling pathways of the body,s fight ... system of the inner ear that sets baseline hearing ... "Our research shows, for the first time, that the ...
Cached Medicine News:Health News:FDA Reviews Side Effects From Prostate Cancer Therapy 2Health News:President Bill Clinton and South African Health Minister Aaron Motsoaledi to join 25,000 scientists, people living with HIV, and other stakeholders at XVIII International AIDS Conference in Vienna 2Health News:President Bill Clinton and South African Health Minister Aaron Motsoaledi to join 25,000 scientists, people living with HIV, and other stakeholders at XVIII International AIDS Conference in Vienna 3Health News:President Bill Clinton and South African Health Minister Aaron Motsoaledi to join 25,000 scientists, people living with HIV, and other stakeholders at XVIII International AIDS Conference in Vienna 4Health News:Revolution with a salad spinner 2Health News:Involved Parents Less Likely to Raise Bullies 2Health News:Survivors of childhood cancers 4 times more likely to develop post-traumatic stress disorder 2Health News:Survivors of childhood cancers 4 times more likely to develop post-traumatic stress disorder 3Health News:A stress-response system in the ear protects against hearing loss 2Health News:A stress-response system in the ear protects against hearing loss 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: